Santen has announced that SAKURA Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus...
Positive data from two clinical studies of MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System indicates that it may provide...
This study was designed to compare 3 immunosuppression regimens: sirolimus and tacrolimus versus everolimus and tacrolimus versus mycophenolate and tacrolimus.
This is a multi-center, double-blinded, randomized, placebo-controlled, phase 2 study to evaluate the efficacy and safety of sirolimus administered in addition to standard therapy, in patients with active SLE disease.
Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Rapamune may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued (see sections 4.2 and 5.1). Rapamune is indicated for the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function (see sections 4.2 and 5.1).
While calcineurin inhibitors (CNI s) are effective for preventing acute rejection in kidney transplant recipients, long‐term use may cause chronic kidney injury and is associated with increased risks of cardiovascular events, cancer, and infection‐associated death.
Pfizer Inc.announced that the FDA has approved Rapamune (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that...
Inhibitors of mechanistic target of rapamycin (mTOR inhibitors) are used as antiproliferative immunosuppressive drugs and have many clinical applications in various drug combinations.
Nobelpharma Co., Ltd. announced that Hyftor (sirolimus 2mg/g) has been launched in the EU/EEA countries and the United Kingdom for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and children aged 6 years and older